Ashton Thomas Private Wealth’s Halozyme HALO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.6M Sell
14,483
-1,701
-11% -$164K 0.03% 445
2026
Q2
$1.27M Buy
16,184
+950
+6% +$64.8K 0.03% 495
2026
Q1
$985K Buy
15,234
+5,648
+59% +$398K 0.02% 543
2025
Q4
$645K Buy
9,586
+343
+4% +$23.1K 0.02% 602
2025
Q3
$678K Buy
9,243
+2,379
+35% +$158K 0.02% 576
2025
Q2
$357K Buy
6,864
+2,694
+65% +$153K 0.01% 642
2025
Q1
$266K Buy
+4,170
New +$242K 0.01% 687
2024
Q4
– Sell
-3,791
Closed -$217K – 787
2024
Q3
$217K Buy
3,791
+71
+2% +$4.07K 0.01% 574
2024
Q2
$195K Buy
+3,720
New +$163K 0.01% 571
2022
Q3
– Sell
-27,986
Closed -$1.23M – 461
2022
Q2
$1.23M Sell
27,986
-608
-2% -$26.3K 0.13% 187
2022
Q1
$1.14M Buy
28,594
+5,429
+23% +$193K 0.1% 229
2021
Q4
$931K Buy
+23,165
New +$865K 0.09% 250

Other funds holding HALO

Ashton Thomas Private Wealth's HALO Position: Q3 2026 in Review

Ashton Thomas Private Wealth reduced its Halozyme (HALO) stake by 11% in Q3 2026, selling an estimated $164K and leaving 14,483 shares worth $1.6M. The position accounts for 0.03% of the portfolio, ranked #445.

Ashton Thomas Private Wealth first reported a position in HALO in Q4 2021 and has held it in 12 quarters since. 773 funds tracked by Wall St. Rank hold HALO as of Q3 2026.

  • Ashton Thomas Private Wealth held 14,483 shares of Halozyme worth $1.6M as of Q3 2026.
  • Ashton Thomas Private Wealth sold 1,701 Halozyme shares in Q3 2026, an estimated $164K.
  • Halozyme made up 0.03% of Ashton Thomas Private Wealth's portfolio in Q3 2026, its #445 holding.
  • Ashton Thomas Private Wealth first reported a position in Halozyme in Q4 2021 and has held it in 12 quarters since.
  • 773 funds tracked by Wall St. Rank held Halozyme as of Q3 2026.

Based on Ashton Thomas Private Wealth's 13F filing for Q3 2026, filed 3 Nov 2026.